Abstract
In the general population, dyslipidemia is an established independent risk factor for cardiovascular disease. In patients with end-stage renal disease (ESRD), comorbid cardiovascular disease is present at alarming rates, and those who require hemodialysis and have cardiovascular disease continue to have a high mortality rate. Lipid abnormalities associated with chronic kidney disease (CKD) vary depending on the stage of disease (stages 1-5), but low-density lipoprotein cholesterol (LDL) has been established as the primary lipid treatment target. Guidelines support an LDL level of less than 100 mg/dl in patients with all stages of CKD, except when the triglyceride level is above 500 mg/dl. As patients progress to stage 5 CKD (ESRD with hemodialysis), the high triglyceride, low high-density lipoprotein cholesterol, and increased lipoprotein(a) levels of the early stages become more pronounced, with increases in small dense LDL particles; however, total cholesterol and LDL values remain normal or decrease. In patients undergoing hemodialysis, lipid abnormalities are driven by an increase in hepatic secretion and delayed catabolism of very low-density lipoproteins, as well as a reduction in lipoprotein lipase and hepatic lipase. Ep...Continue Reading
References
May 1, 1996·Kidney International·P S ParfreyP E Barre
Nov 20, 1998·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·R N FoleyM J Sarnak
Jul 8, 2000·Kidney International·A K CheungA S Levey
May 23, 2001·JAMA : the Journal of the American Medical Association·UNKNOWN Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults
Jan 12, 2002·Kidney International·Stephen L SeligerCatherine O Stehman-Breen
Apr 16, 2003·Kidney International. Supplement·Colin Baigent, Martin Landry
Oct 29, 2003·Circulation·Mark J SarnakUNKNOWN American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology,
Jul 14, 2004·Circulation·Scott M GrundyUNKNOWN American Heart Association
Nov 5, 2004·Clinical Nephrology·R L LinsY A Carpentier
Jun 7, 2005·Postgraduate Medical Journal·G D KolovouD V Cokkinos
Jul 22, 2005·The New England Journal of Medicine·Christoph WannerUNKNOWN German Diabetes and Dialysis Study Investigators
Jan 21, 2006·Seminars in Dialysis·Jia Liu, Mitchell H Rosner
Jan 31, 2006·Hemodialysis International·Nosratola D Vaziri, Hamid Moradi
Aug 1, 2006·Journal of the American College of Cardiology·Christopher P CannonEugene Braunwald
Mar 9, 2007·Atherosclerosis·Doris T ChanGerald F Watts
Mar 16, 2007·Journal of the American Society of Nephrology : JASN·Bonnie C H KwanAlfred K Cheung
Aug 21, 2007·Clinical Journal of the American Society of Nephrology : CJASN·My SvenssonUNKNOWN OPACH Study Group
Dec 7, 2007·Lancet·UNKNOWN Prospective Studies CollaborationRory Collins
Feb 27, 2008·BMJ : British Medical Journal·Giovanni F M StrippoliJonathan C Craig
Jun 21, 2008·Journal of the American College of Cardiology·Charles R Harper, Terry A Jacobson
Jul 10, 2008·American Journal of Nephrology·Vasilis TsimihodimosKostas C Siamopoulos
Dec 17, 2008·Circulation·Donald Lloyd-JonesUNKNOWN American Heart Association Statistics Committee and Stroke Statistics Subcommittee
Feb 13, 2009·Current Medical Research and Opinion·Bengt FellströmUNKNOWN AURORA Study Group
Apr 1, 2009·The New England Journal of Medicine·Bengt C FellströmUNKNOWN AURORA Study Group
Jul 2, 2009·BMJ : British Medical Journal·J J BrugtsJ W Deckers
Citations
Mar 30, 2011·European Heart Journal·Luis M Ruilope, George L Bakris
Nov 8, 2014·Seminars in Dialysis·Mitchell H Rosner, Madhukar Misra
Jan 19, 2018·Cardiorenal Medicine·Kenneth M BorowKrishnaswami Vijayaraghavan
Mar 29, 2019·European Journal of Clinical Investigation·Towe StrålbergErik Nilsson
Oct 28, 2010·Expert Opinion on Pharmacotherapy·Patrick Biggar, Markus Ketteler
Nov 20, 2020·Seminars in Dialysis·Katie E Cardone, Wendy M Parker